Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney Cancer (PRISM care)
Metastatic Renal Cell Carcinoma
About this trial
This is an interventional supportive care trial for Metastatic Renal Cell Carcinoma focused on measuring Oral chemotherapy, Relative dose intensity, Health related program, Secured drug intake
Eligibility Criteria
Inclusion Criteria:
- Patient aged 18 years old or more
- With metastatic renal cell carcinoma
- With an initiation or change of oral targeted therapy, especially: tyrosine kinase inhibitor (sunitinib, sorafenib, pazopanib, axitinib) or mTor inhibitor (everolimus)
- With ambulatory status (not hospitalized for the management and treatment of its metastatic renal cell carcinoma)
- Without either cognitive disorders or major psychiatric disorders
- With a sufficient autonomy for the management of medication at home
- Having declared an outpatient doctor
- Having declared a usual pharmacy
- Having given his written consent to participate in the study
Exclusion Criteria:
- Significant cognitive and psychiatric disorders
- Management of medication at home exclusively performed by the family caregiver
- Patient in an institution or under guardianship, major protected by law
- Patient refusing to participate in the study
Sites / Locations
- Institut de Cancérologie de l'OuestRecruiting
- CH de ChambéryRecruiting
- Centre de Lutte Contre le Cancer Jean PerrinRecruiting
- Centre Léon BérardRecruiting
- Hôpital Arnaud de VilleneuveRecruiting
- APHP Hôpital de la Pitié SalpétrièreRecruiting
- Hospices Civils de Lyon Groupement Hospitalier Sud Service pharmaceutique Unité de Pharmacie Clinique Oncologique Pavillon Marcel Bérard 1G 165 chemin du Grand RevoyetRecruiting
- Institut Jean Godinot de ReimsRecruiting
- CHURecruiting
- ICL Institut de Cancérologie de la Loire Lucien NeuwirthRecruiting
- Hôpital BretonneauRecruiting
- CH LacariRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
PRISM care program
Standard of care
PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
In the group with standard of care, patients will have interviews with a hospital pharmacist only dedicated to the record of data for outcomes assessment. These sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion , and at the end at month 6 after the final physical session.